<DOC>
	<DOCNO>NCT02564588</DOCNO>
	<brief_summary>Evaluate efficacy flexibly-dosed dasotraline compare placebo adult moderate severe Binge Eating Disorder ( BED )</brief_summary>
	<brief_title>Dasotraline Binge Eating Disorder Study</brief_title>
	<detailed_description>This randomize , double blind , parallel group , multicenter , outpatient study evaluate efficacy safety flexibly-dosed dasotraline adult BED use dasotraline ( 4 , 6 , 8 mg/day ) versus placebo 12 week treatment period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<criteria>Male female subject 18 55 year age , inclusive , time informed consent . Subject meet follow DSM 5 criterion diagnosis BED . An episode binge eat characterize : Eating amount food large people would eat , discrete period time ( eg , 2 hour ) Sense lack control eat episode Bingeeating episode associate ≥ 3 following : Eating much rapidly normal Eating uncomfortably full Eating large amount feel hungry Eating alone embarrassment Feeling disgust oneself , guilty afterward Bingeeating episode also associate mark distress regard episode associate recurrent use compensatory behavior ( eg , bulimia nervosa ) . Diagnosis confirm base eatingdisorders module SCID , clinician review subject diary , EDE Q . Subject BED diagnosis include least 2 binge eating day week least 6 month prior screen . Subject 's BED least moderate severity . Subject negative breath alcohol test negative urine drug screen ( UDS ) illicit drug . Female subject must negative serum pregnancy test screening ; female postmenopausal ( define least 12 month spontaneous amenorrhea ) undergone hysterectomy bilateral oophorectomy exempt pregnancy test . Female subject childbearing potential male subject female partner childbearing potential must agree use effective medically acceptable form birth control throughout study period . Note : Continued use effective medically acceptable form birth control recommend 30 day study completion . Subject must able comply study drug administration adhere protocol requirement . Subject read well enough understand informed consent form subject material . Subject body weight index ( BMI ) 18 kg/m2or less great 45 kg/m2 . Subject lifetime history current symptom bulimia nervosa anorexia nervosa . Subject start psychotherapy ( eg , supportive psychotherapy , cognitive behavior therapy , interpersonal therapy ) within 3 month prior screen . Note : Subjects receive stable ongoing psychotherapy longer 3 month permit enroll . Subject participate formal weight loss program ( eg , Weight Watchers® ) within 3 month prior screen . Subject use psychostimulant mood stabilizer within 3 month prior screen . Subject use medication treatment binge eating , eat disorder , obesity , weight gain medication could result weight gain weight loss include overthecounter herbal product within 3 month prior screen . Subject lifetime history psychotic disorder , bipolar disorder , hypomania , dementia , ADHD define DSM 5 criterion . Subject history moderate severe depression base investigator 's judgment within 6 month prior screen currently take take medication depression 3 month prior screen . Subject history substance use disorder include alcohol use disorder ( exclude nicotine caffeine ) within 12 month prior screen , define DSM 5 criterion . Subject MADRS score ≥ 18 screen Baseline visit . Subject consider suicide risk previous history suicide attempt . Subject answer `` yes '' `` suicidal ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) C SSRS assessment screening ( past month ) . Subjects answer `` yes '' question must refer Investigator follow evaluation . Subject type I diabetes mellitus insulindependent diabetes mellitus . Subject type II diabetes mellitus hemoglobin A1c ≥ 6.5 % screening , initiate treatment change dose glucoselowering agent within 3 month prior screen . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , document heart rhythm abnormality , coronary artery disease , serious cardiac problem . Subject initiate treatment change dose lipidlowering medication within 3 month prior screen . Subject history moderate severe hypertension investigator 's opinion medically stable require change dosage and/or medication 3 month prior screen . Subject history epilepsy , seizure ( except childhood febrile seizure ) , unexplained syncope unexplained blackout ( except single incident ) , head trauma loss consciousness last 5 minute , history clinically significant repeat headtraumas without loss consciousness . Subject female pregnant nursing . Subject bariatric surgery , lap band , duodenal stent , procedure weight loss . Subject history positive test Hepatitis B surface antigen Hepatitis C antibody liver function test result screen upper limit normal ( ULN ) reference laboratory . Subject without history positive test Hepatitis B surface antigen Hepatitis C antibody alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value ≥ 2 time ULN screening . Subject blood urea nitrogen ( BUN ) value ≥ 1.5 time ULN reference range , fast blood glucose ≥ 126 mg/dL ( 7.0 mmol/L ) , hemoglobin A1c ≥ 6.5 % screening . Subject know tested positive human immunodeficiency virus ( HIV ) . Subject clinically significant abnormality screen evaluation include physical examination , vital sign , ECG , laboratory test investigator considers inappropriate allow participation study . The subject 's screening ECG show correct QT interval use Fridericia 's formula ( QTcF ) ≥ 450 msec male subject ≥ 470 msec female subject . Eligibility base core laboratory ECG interpretation report . Subject lifetime history abuse diversion stimulant . Subject history allergic reaction know suspected sensitivity substance contain study drug formulation . Subject enrol Phase 2 3 trial psychostimulants include lisdexamfetamine dimesylate ( Vyvanse® ) bingeeating disorder . Subject currently participate participate clinical trial within last 90 day participate 2 clinical trial within past year . This include study use marketed compound device . Subject previously enrol clinical trial dasotraline ( SEP 225289 ) . Subject investigational site staff member relative investigational site staff member .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>